SAN

80.63

-0.11%↓

SHL.DE

41.85

-0.38%↓

ORNBV.FI

68.4

-0.44%↓

QDEL

23.99

+13.64%↑

ACB

3.82

+0.79%↑

SAN

80.63

-0.11%↓

SHL.DE

41.85

-0.38%↓

ORNBV.FI

68.4

-0.44%↓

QDEL

23.99

+13.64%↑

ACB

3.82

+0.79%↑

SAN

80.63

-0.11%↓

SHL.DE

41.85

-0.38%↓

ORNBV.FI

68.4

-0.44%↓

QDEL

23.99

+13.64%↑

ACB

3.82

+0.79%↑

SAN

80.63

-0.11%↓

SHL.DE

41.85

-0.38%↓

ORNBV.FI

68.4

-0.44%↓

QDEL

23.99

+13.64%↑

ACB

3.82

+0.79%↑

SAN

80.63

-0.11%↓

SHL.DE

41.85

-0.38%↓

ORNBV.FI

68.4

-0.44%↓

QDEL

23.99

+13.64%↑

ACB

3.82

+0.79%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

81.6 4.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

77.3

Max

82.5

Põhinäitajad
By Trading Economics
Sissetulek	49M 76M
Müük	51M 210M
P/E Sektori keskmine	32.945 108.767
Aktsiakasum	1.135
Dividenditootlus	1.2
Kasumimarginaal	35.965
Töötajad	2,197
EBITDA	49M 84M

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	1.20% 2.21%
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	742M 4B
Eelmine avamishind	77.39
Eelmine sulgemishind	81.6

Uudiste sentiment

By Acuity

24%

76%

52 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

51.1 / N/A Toetus ja vastupanu

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. veebr 2026, 23:07 UTC

Tulu

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 23:01 UTC

Tulu

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:59 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24. veebr 2026, 22:42 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24. veebr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24. veebr 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24. veebr 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24. veebr 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24. veebr 2026, 23:16 UTC

Tulu

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24. veebr 2026, 23:13 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24. veebr 2026, 23:12 UTC

Tulu

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24. veebr 2026, 23:08 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24. veebr 2026, 23:07 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24. veebr 2026, 22:52 UTC

Tulu

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 22:46 UTC

Tulu

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Warner Receives New Bid From Paramount -- 3rd Update

24. veebr 2026, 22:29 UTC

Tulu

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24. veebr 2026, 22:28 UTC

Tulu

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24. veebr 2026, 22:25 UTC

Tulu

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24. veebr 2026, 22:24 UTC

Tulu

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24. veebr 2026, 22:23 UTC

Tulu

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24. veebr 2026, 22:22 UTC

Tulu

Woolworths Interim Dividend 45 Australian Cents/Share

24. veebr 2026, 22:22 UTC

Tulu

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24. veebr 2026, 22:21 UTC

Tulu

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

51.1 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

52 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.